Citations

Showing 10 of 107966 citations.

Antifouling Immunomodulatory Copolymer Architectures That Inhibit the Fibrosis of Implants
Jeang, William J. , Jiang, Alexis L., Bose, Suman , Collins, Evan , McMullen, Patrick , Rosenboom, Jan‐Georg , Lathwal, Sushil , Langer, Robert , Anderson, Daniel G , Wong, Bryan Matthew , Zhao, Yichao , Manan, Rajith S. , Langer, Róbert , Anderson, Daniel G.

Mayo Clinic

Advanced Materials | December 25, 2024 | Volume: 37 | Issue: 7 | Pages: No page available

10.1002/adma.202414743 | PMID 39722171 Get It

Abstract Immune reactions to medical implants often lead to encapsulation by fibrotic tissue and impaired device function. This process is thought to initiate by protein adsorption, which enables immune cells to attach and mount an inflammatory response. Previously, several antifibrotic materials have been either designed to reduce protein adsorption or discovered via high‐throughput screens (HTS) to favorably regulate inflammation. The present work introduces antifouling immunomodulatory (AIM) copolymer coatings, which combine both strategies to effectively enhance implant protection. AIM copolymers synergistically integrate zwitterionic moieties to resist protein fouling, HTS‐derived antifibrotics for immunomodulation, and silane monomers for grafting to diverse substrates including elastomers, ceramics, and metals. Interestingly, simply combining these monomers into conventional random or block copolymer architectures yielded no significant advantage over homopolymers. By contrast, an unusual polymer chain architecture — a zwitterionic block flanked by a mixed zwitterionic immunomodulatory segment — showed superior fibrosis resistance in both peritoneal and subcutaneous sites over one month in immunocompetent mice. This architecture also improved the performance of two different HTS‐derived antifibrotic monomers, suggesting that tailoring AIM architectures may broadly complement immunomodulatory chemistries and provide a versatile approach to improving implant longevity.
Impact of Demographics and Psychological Factors on Three-Day Postoperative Pain Perception Following Hand Surgery
Ho, Olivia A. , Haider, Syed Ali , Genovese, Ariana , Prabha, Srinivasagam , Haider, Clifton R. , Felton, Christopher L. , Carter, Rickey E. , Forte, Antonio J. , Haider, Clifton R , Felton, Christopher L , Bruce, Charles J. , Carter, Rickey E , Forte, Antonio Jorge , Haider, Syed A , Genovese, Ariana , Prabha, Srinivagasam , Borna, Sahar , Gomez-Cabello, Cesar A. , McLeod, Christopher J.

Mayo Clinic

Journal of Clinical Medicine | December 25, 2024 | Volume: 14 | Issue: 1 | Pages: 37

10.3390/jcm14010037 | PMID 39797119 Get It

Background: Effective pain management is crucial for both comfort and outcomes, yet predicting and managing this pain is difficult. This study aimed to analyze postoperative pain in patients undergoing hand surgery at the Mayo Clinic Florida, examining how patient characteristics and anxiety affect pain outcomes. Methods: We conducted a single-arm clinical trial at Mayo Clinic Florida, recruiting patients undergoing hand surgery. Preoperative pain and anxiety were assessed using the Pain Catastrophizing Scale (PCS) and State-Trait Anxiety Inventory (STAI). Postoperatively, patients used an iPhone app to record pain levels and medication use every four hours. Devices were collected three days after surgery. We analyzed the relationship between demographics, PCS, STAI scores, and pain levels using linear and logistic regression models. All statistical tests were two-sided with significance set at p < 0.05, analyzed with R4.2.2. Results: Data were collected from 62 patients (62.9% women, 37.1% men) undergoing hand surgery. Participants were mainly White (90.3%), with 50% being in the middle-aged adult group. Most had low anxiety levels (80.6% STAI-S, 82.3% STAI-T) and low catastrophizing (61.3% PCS). Postoperative pain was low, with median scores between 1.0 and 2.0 over three days. Demographics, anxiety, and catastrophizing were not significant predictors of pain levels. Logistic regression showed time as a significant factor, with pain levels peaking on Day 3. Conclusions: Postoperative pain after hand surgery was generally low, with time being a significant predictor of increased pain. Demographic factors, anxiety, and catastrophizing did not significantly affect pain levels. Pain management should emphasize time-sensitive interventions and ongoing monitoring.
Emerging Trends in Non-Invasive Brain Stimulation: The New Kids on the Block
Croarkin, Paul E. , Croarkin, Paul E , Brunoni, André R. , Razza, Laís Boralli

Mayo Clinic

Biomedicines | December 25, 2024 | Volume: 13 | Issue: 1 | Pages: 14

10.3390/biomedicines13010014 | PMID 39857598 Get It

In the Sustainable Development Goals of the United Nations for 2030, mental health has been identified as a global priority, emphasizing the need to reduce the prevalence, morbidity, and premature mortality associated with mental disorders [...]
Lessons Learned: Preventing Faculty Burnout
Hoffmann, Chelsey

Mayo Clinic

The Journal of Physician Assistant Education | December 25, 2024 | Volume: 36 | Issue: 3 | Pages: e320-e322

10.1097/jpa.0000000000000648 | PMID 39721067 Get It

Introduction Physician Assistant/Associate (PA) clinicians face a major learning curve when transitioning from patient provider to PA educator. Furthermore, PA educators juggle multiple responsibilities including teaching, grading, advising, mentoring, interviewing, researching, writing, and more. Recently published research has indicated that 52.4% of PA educators thought about leaving their faculty roles within the past year. To assist in the effort to prioritize faculty retention, a personal story of faculty burnout and lessons learned is shared. Methods Burnout and its three associated subscales are defined, while symptoms of burnout are outlined in a manner specific to the role of a PA faculty member. Results Drawing from the existing evidence base, suggestions are made to improve the well-being of PA educators and prevent faculty burnout or turnover. Discussion While being a PA faculty member is extremely rewarding, it can also be challenging, particularly for early-career PAs or those transitioning from clinical practice with no prior work experience as an educator. Strategic implementation of good habits may aid faculty members in preventing burnout and improving work-life balance.
Expert consensus recommendations on dermoscopy proficiency standards for physician assistants: results of a modified Delphi survey
Young, Peter A. , Middleton, Hayden T. , Froiland, Christi, Keeter, Nicole, Sanders, Kim B., DiRuggiero, Douglas , Pettey, Adam A., Swanson, David C. , Marghoob, Ashfaq A. , McCleskey, Patrick E. , Seiverling, Elizabeth V. , Griffith, Cynthia Faires , Sanders, Kim B., Bae, Gordon Hyeonjin , Mostaghimi, Arash , Nelson, Kelly C.

Mayo Clinic

Journal of Dermatology for Physician Assistants | December 25, 2024 | Volume: 19 | Issue: 1 | Pages: 14-19

10.1097/jdpa.0000000000000047 Get It

Importance: Dermoscopy is increasingly recognized by skin cancer experts and professional leaders as an essential skill for physicians in dermatology and primary care. A substantial number of patients in both settings also receive care from physician assistants (PAs), who provide additional opportunities to evaluate patients with concerning skin lesions. Earning dermatology-specific credentials from the National Commission on Certification for PAs requires passing a written exam with dermoscopic content, and 77% of practicing PAs (all specialties) believe dermoscopy should be a standard element of their formal education. No published studies have identified precise learning objectives that would represent appropriate foundational proficiency in dermoscopy for PAs. Objective: We sought to identify common diagnoses with distinct dermoscopic features and delineate which of these represent appropriate proficiency expectations for early-career PAs in primary care and dermatology. Design, setting, and participants: A panel of 14 dermoscopists was assembled (8 dermatologists; 6 PAs), reflecting contributors to existing consensus statements on physician dermoscopy proficiency benchmarks, dermatologist-recommended competencies for PAs, and/or standardized test content for dermatology PAs. Panelists completed a modified Delphi consensus process involving electronic surveys and roundtable discussions. Main outcomes and measures: Consensus on which specific dermoscopic diagnoses reflect appropriate foundational proficiency expectations for PAs in both primary care and dermatology. Results: Twelve of 14 panelists (86%) reported using dermoscopy for over 12 years (mean: 15.5 y). All panelists completed 2 iterations of an electronic survey regarding 54 diagnoses, with 39 (72%) reaching a final consensus for inclusion in PA curricula and 15 (28%) being identified as non-priority items for early-career PAs. Panelists recommended 14 conditions for primary care PAs and 25 conditions for dermatology PAs. Conclusions and Relevance: Consensus achieved in this modified Delphi process identified diagnoses that represent pragmatic learning objectives to achieve foundational proficiency in dermoscopy for PAs in both primary care and dermatology. This list of validated objectives provides a consensus-based guide to help educators, supervising physicians, and professional leaders to cultivate specialty-appropriate dermoscopic proficiency among early-career PAs.
Characterizing the antibody response to amustaline/glutathione pathogen‐reduced red blood cells
Karim, Christopher, Panigrahi, Anil K. , Pearl, Ronald G. , Sodha, Neel R. , Beaver, Thomas M. , Pelletier, J. Peter R. , Nuttall, Gregory A. , Reece, T. Brett , Erickson, Anna , Hedrick, Teresa, Bentow, Stanley, Mufti, Nina, Varrone, Jeanne, Corash, Laurence M , Benjamin, Richard J , Hedrick, Teresa, Liu, Kathy

Mayo Clinic

Transfusion | December 25, 2024 | Volume: 65 | Issue: 2 | Pages: 344-353

10.1111/trf.18117 | PMID 39719927 Get It

AbstractBackgroundThe clinical significance of natural and treatment‐emergent antibodies specific for amustaline/glutathione pathogen‐reduced red blood cells (PRRBCs) is not known.Study Design and MethodsA Phase 3, randomized clinical trial of PRRBCs (ReCePI) compared PRRBCs with conventional RBCs in cardiac or thoracic‐aorta surgery. Subjects transfused during and for 7 days after surgery were screened for PRRBC‐specific antibodies at baseline, 28 and 75 days post‐surgery. Subjects with treatment‐emergent antibodies were assessed for evidence of hemolysis. Cryopreserved subject RBC samples were assayed by flow cytometry for circulating PRRBCs using an acridine‐specific (2S197‐2M1) monoclonal antibody, and for human IgG‐coated RBCs. RBC‐surface acridine density was quantitated using a commercial calibrated phycoerythrin (PE)‐bead panel.ResultsFive of 159 (3.1%) PRRBC and zero of 162 conventional RBC recipients developed treatment‐emergent PRRBC‐specific IgG, low titer antibodies detected 26–80 days post‐surgery after exposure to 1–3 PRRBC units, without clinical evidence of hemolysis. DAT and eluate were weak (w+) positive and PRRBC‐specific in one subject. A monocyte monolayer assay (MMA) was non‐reactive in the three subjects with an interpretable result. Flow cytometry demonstrated circulating PRRBCs in all five subjects expressing surface acridine concentrations at the limit of detection (approximately 150–301 PE molecules/RBC) compared with freshly transfused PRRBCs (approximately 7500 PE molecules/RBC). In some samples, loss of surface acridine expression could not be distinguished from clearance of the PRRBCs.DiscussionTreatment‐emergent PRRBC‐specific antibodies with the characteristics of nonclinically significant antibodies were detected in five subjects transfused with PRRBCs. Flow cytometry demonstrated persistent circulating PRRBCs with minimal surface acridine expression. (www.ClinicalTrials.gov Identifier NCT03459287).
Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
Katz, Philip O. , DeVault, Kenneth R. , Metz, David C., Tamene, David, Smith, Neila, Hunt, Barbara, Katz, Philip , Howden, Colin W. , Chang, Yu‐Ming , Spechler, Stuart Jon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 25, 2024 | Volume: 61 | Issue: 5 | Pages: 835-851

10.1111/apt.18458 | PMID 39720884 Get It

ABSTRACT Background Patients with erosive oesophagitis, and those with persistent symptomatic non‐erosive gastro‐oesophageal reflux disease, require long‐term maintenance treatment with acid‐suppressing agents. Aim To evaluate the safety of vonoprazan, a potassium‐competitive acid blocker, in an integrated analysis of data from clinical trials in adults. Methods We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person‐years to vonoprazan ( n = 5318) was 2068, to comparators lansoprazole ( n = 1925) or esomeprazole ( n = 86) was 751, and to placebo ( n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post‐marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided. Results Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person‐years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug. Conclusions Vonoprazan was well tolerated. Its safety profile from both clinical trial and post‐marketing data were consistent and comparable to that of its PPI comparators with respect to treatment‐emergent adverse events.
DEK::AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma
Hart, Stephanie A , Mikula, Michael W. , Amin, Sara E. , Saluja, Karan , Chen, Y., David, Stephanie N., Dupont, William D., Plummer, W. Dale, Ferrer, Karen, Geromes, Ariana, Hsieh, Min-Shu, Kuo, Ying‐Ju , Sasaki, Eiichi , Shi, Qiuying , Truong, Tra , Lewis, James S. , Lewis, James S , Hang, Jen‐Fan , Chernock, Rebecca , Rooper, Lisa M. , Bishop, Justin A. , Cipriani, Nicole A. , Hsieh, Min‐Shu , Hernandez‐Prera, Juan C. , Torres, Jaylou M. Velez

Mayo Clinic

American Journal of Surgical Pathology | December 25, 2024 | Volume: 49 | Issue: 2 | Pages: 130-137

10.1097/pas.0000000000002335 | PMID 39719672 Get It

DEK::AFF2 fusion nonkeratinizing squamous cell carcinoma (NKSCC) is an emerging entity in the sinonasal tract, temporal bone, and skull base. However, the clinical behavior of these tumors has not been well studied. Here, we report the largest cohort of DEK::AFF2 carcinomas to determine if morphology, mitotic rate, and/or Ki-67 IHC are associated with patient outcomes, including a comparison with high-risk human papillomavirus (HPV)-associated and independent patients. We solicited cases of molecularly or AFF2 immunohistochemistry (IHC) proven DEK::AFF2 SCC from surgical pathologists to collect patient demographic, clinical, and outcome data. Using representative H&E slides, we characterized the morphology and counted mitoses. Ki-67 immunohistochemistry was performed. We also compared the DEK::AFF2 survival rates to those in a cohort of AFF2 IHC-negative HPV-associated and HPV-independent SCC. DEK::AFF2 carcinomas most commonly arose in the nasal cavity (13/30, 43%), and the average number of recurrences was 1.8 (range: 0 to 10). At the last follow-up, most patients were disease free (19/30, 63%) or were alive with disease (9/30, 30%). There was an average mitotic rate of 2 per 2 mm2 (range: 0 to 9) and Ki-67 proliferation rate of 26% (range: 3% to 60%). Local recurrence was common, but morphology, mitotic activity, and Ki-67 index were not associated with recurrence or survival. On Kaplan-Meier survival analysis, DEK::AFF2 patients had lower disease-free survival but otherwise had similar outcomes to conventional SCC patients. Our multi-institutional study shows that local recurrence is common in DEK::AFF2 fusion nonkeratinizing SCC patients, but patients have survival rates similar to conventional SCC. Despite showing a range of different features and proliferation rates, traditional grading by morphology, mitotic rate, and/or Ki-67 activity does not seem to be predictive of outcome.
Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON‐HF
Lu, Henri , Inciardi, Riccardo M. , Abanda, Martin Hongieh , Shah, Amil M. , Čikeš, Maja , Claggett, Brian , Prasad, Narayana , Lam, Carolyn S.P. , Redfield, Margaret M. , McMurray, John J.V. , Solomon, Scott D. , Abanda, Martin , Claggett, Brian L , Redfield, Margaret M , Pfeffer, Marc Alan , Solomon, Scott David , Hegde, Sheila M , Skali, Hicham , McMurray, John J V , Lam, Carolyn S P , Shah, Amil , Hegde, Sheila M. , Skali, Hicham

Mayo Clinic

Journal of the American Heart Association | December 24, 2024 | Volume: 14 | Issue: 1 | Pages: No page available

10.1161/jaha.124.037380 | PMID 39719412 Get It

Background This study aims to characterize right ventricular dysfunction (RVD) in heart failure (HF) with preserved ejection fraction and understand the cumulative prognostic value of abnormal RV echocardiographic parameters in HF with preserved ejection fraction. Methods and Results Data from 809 patients in the PARAGON‐HF (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor With Angiotensin‐Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction) echocardiographic substudy (55% women, mean age 74±8 years) were analyzed. Correlates of RVD (defined as tricuspid annular plane systolic excursion <1.7 cm, fractional area change <35% or absolute RV free wall longitudinal strain <20%) were identified using multivariable logistic regression models. We further assessed the prognostic value of the number of abnormal RV parameters (0, 1, ≥2) on total HF hospitalizations (HFH) and cardiovascular death, total HFH, first HFH or cardiovascular death, all‐cause death, and cardiovascular death. RVD was identified in 461 (57%) patients. Correlates of RVD included older age, higher heart rate, atrial fibrillation/flutter, greater left ventricle wall thickness, higher N‐terminal pro‐B‐type natriuretic peptide levels, lower systolic blood pressure, and lower left ventricle absolute global longitudinal strain. These results were consistent across sexes, except atrial fibrillation/flutter and LV wall thickness, which were associated with a higher risk of RVD in men but not in women. Participants with ≥2 abnormal RV parameters had a significantly higher adjusted risk of total HFH and cardiovascular death (rate ratio, 2.13 [95% CI, 1.13–4.01]), first HFH or cardiovascular death, all‐cause death, and cardiovascular death. Conversely, an isolated abnormal RV parameter was not associated with a worse outcome. Conclusions RV measures may underestimate the burden of RVD in HF with preserved ejection fraction when considered in isolation. Clinicians should consider multiple dimensions to comprehensively assess RV function in patients with HF with preserved ejection fraction.